Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RenascienceTSE:4889 -2.25%53 Current Ratio is 19.40 as of Mar. 2026, which is 14% below its 10-year median of 22.64. GuruFocus rates TSE:4889 with a GF Score™ of 53/100 and a GF Value™ of 円331.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Renascience ranks better than 98.13% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Renascience's current ratio for the quarter that ended in Mar. 2026 was 19.40.
Renascience has a current ratio of 19.40. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Renascience's Current Ratio or its related term are showing as below:
TSE:4889'
s Current Ratio Range Over the Past 10 Years
Min: 12.38 Med: 22.64 Max: 89.31
Current: 19.4
During the past 7 years, Renascience's highest Current Ratio was 89.31. The lowest was 12.38. And the median was 22.64.
TSE:4889's Current Ratio is ranked better than 98.13% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.5
vs TSE:4889: 19.40
Renascience (TSE:4889) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Renascience Current Ratio Related Terms
Renascience Current Ratio Historical Data
* Premium members only.
The historical data trend for Renascience's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4889 vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, Renascience's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renascience Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Renascience's Current Ratio distribution charts can be found below:
* The bar in red indicates where Renascience's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renascience (TSE:4889) has a Current Ratio of 19.40 as of Mar. 2026. This is 14% below median its historical median of 22.64. Over the past decade, Renascience's Current Ratio has ranged from 12.38 to 89.31. According to the industry distribution chart, Renascience ranks #16 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 1.9%.
Is Renascience's Current Ratio too high?
Renascience's current Current Ratio of 19.40 is 14% below median its 10-year median of 22.64. Over the past 10 years, this metric has ranged from a low of 12.38 to a high of 89.31. The Medical Devices & Instruments industry median Current Ratio is 2.50. Renascience's value of 19.40 is 676% above this industry median. Based on the distribution chart, Renascience ranks #16 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Renascience has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Renascience's Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Renascience ranks #16 out of 854 companies for Current Ratio. This places Renascience in the top 2% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.50. Renascience's value of 19.40 is 676% above this benchmark. Historically, Renascience's own Current Ratio has ranged from 12.38 to 89.31 over the past decade. While the company's 10-year median is 22.64 vs. the industry median of 2.50, Renascience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.50, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renascience's current Current Ratio of 19.40 is 676% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renascience's current Current Ratio is 19.40, which is 14% below median its own 10-year median of 22.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renascience stock overvalued right now?
Based on GuruFocus' analysis, Renascience (TSE:4889) is currently considered Significantly Overvalued. The stock's GF Value™ is 円331.42, compared to a current price of 円1,522.00 — trading 359.2% above its estimated fair value. The current Current Ratio is 19.40, which is 14% below median its 10-year median of 22.64 and 676% above the Medical Devices & Instruments industry median of 2.50. Renascience's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Renascience (TSE:4889), the current Current Ratio is 19.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renascience (TSE:4889) Overvalued in 2026?
Based on GuruFocus' analysis, Renascience stock appears to be overvalued.
The current stock price of 円1,522.00 is trading 359.2% above its estimated GF Value™ of 円331.42.
GuruFocus considers Renascience to be Significantly Overvalued.
Key valuation signals for TSE:4889:
Current Ratio: 19.40 (14% below median its 10-year median of 22.64)
GF Value™: 円331.42 vs. price of 円1,522.00 (359.2% above fair value)
Industry Position: 676% above the Medical Devices & Instruments median (#16 of 854)
No single metric tells the full story. See the TSE:4889 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renascience Inc is engaged in the Development and commercialization of pharmaceuticals, medical devices, pieces of software as a medical device (SaMD) utilizing AI, etc.
53GF Score
Get the complete analysis for TSE:4889
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4889 has been successfully added to your 
